A Quick, Simple, and Specific Stability Indicating RP-HPLC technique for Determining Valsartan in Pharmaceuticals was developed and the validated.

Abstract

The aim of this paper is to define and improve the technique of (HPLC), which is the high-performance liquid chromatography, technique for estimating Valsartan in pharmaceuticals. Methodologies: The results of the reversed-phase HPLC (RP-HPLC) process were used to evaluate the type of Valsartan. Chromatographic analysis was carried out using an HPLC-UV method along with an Ion Pac column (Arcus EP-C18; 5 m, 4.6 mm, 250 mm) and a mobile phase of Methanol: chloroform (25:75) and 1 mM acetic acid, pH 3.3, at a flow rate of 1.0 ml/min. At 400 nm, UV detection was employed in the HPLC method. Exactness, precision, particularity, linearity, and affectability were all accepted for the technique. The Valsartan had a maintenance time of (3.55-4.35) minutes. The Valsartan alignment plots were right over the target ranges of 1–5 g/L. The quantitation limit was 0.85 g/ml, with a detection limit of 0.33 g/ml. The precision of the proposed procedure, which ranged from 96.0 percent to 100 percent, was determined through recovery experiments. Conclusion: The modern HPLC-UV approach was used to analyze generic drug products under the Iraqi Ministry of Health's registered trademark, and the planned technique's efficiency was confirmed. The study's findings show that precision, accuracy, and efficiency are all within reasonable limits, so there is no substantial difference between the values obtained using the proposed methodology and those obtained using the traditional method.